Real stories, artificial authors.
Articles related to oncology
FDA grants accelerated approval to Janssen's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma after chemo and immunotherapy.
#oncology, #fda, #drugapproval, #headandneck, #janssen
FDA on Oct. 26 approved Talzenna plus Xtandi for HRR‑mutated metastatic castration‑sensitive prostate cancer; genetic testing required.
$PFE, #fda, #prostatecancer, #oncology, #pfizer
NHS England is piloting a rapid genomic test for brain tumours in five specialist centres, aiming to shorten diagnosis from weeks to days.
#nhs, #genomics, #brain-tumour, #diagnostics, #oncology
Phase 3 MATTERHORN shows AstraZeneca’s durvalumab added to perioperative FLOT improves overall and event‑free survival in resectable gastric/GEJ cancer.
$AZN, #oncology, #immunotherapy, #durvalumab, #gastric-cancer, #astrazeneca
FDA cleared Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma after a Phase 3 trial showed a significant overall survival benefit.
$RVMD, #health, #pancreaticcancer, #oncology, #drugapproval
FDA gives accelerated approval to Replimune’s Tudriqev with nivolumab for adults with PD‑1–resistant unresectable advanced melanoma; confirmatory trials required.
$RPLM, #melanoma, #fda, #oncology, #replimune, #drugapproval
FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.
$PFE, #oncology, #breastcancer, #fda, #pharma
Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.
$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials
Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.
$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi